A comprehensive view of BioNTech SE. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.
Recent Articles
sample of recent headlines, press releases and get more..
INTERNATIONAL PATENT: BIONTECH SE FILES APPLICATION FOR "COMPOSITIONS AND METHODS FOR TREATMENT OF MELANOMA"
Published:
February 07, 2023
by U.S. Fed News
|
Australia Patent: BioNTech SE, TRON - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz Gemeinnutzige File Application for 'Therapeutic RNA for HPV-positive cancer'
Published:
February 03, 2023
by Australian Government
|
Australia Patent: BioNTech SE Files Application for 'Binding agents for coronavirus S protein'
Published:
February 03, 2023
by Australian Government
|
Australia Patent: TRON - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz Gemeinnutzige, BioNTech SE File Application for 'INDIVIDUALIZED VACCINES FOR CANCER'
Published:
February 03, 2023
by Australian Government
|
BioNTech complete construction of company’s first proprietary plasmid DNA manufacturing facility in Marburg, Germany; new facility will strengthen firm’s manufacturing capabilities, allow BioNTech to make the majority of its DNA plasmids in house
Published:
February 02, 2023
by GlobeNewswire
|
Ask us about our Government & Public Policy market view
Trending Chart
Interactive chart with headline count